Industry News

Qiagen Acquires Bioinformatics Firm OmicSoft

By Labmedica International staff writers
12 Jan 2017

Image: QIAGEN has acquired OmicSoft, a bioinformatics company (Photo courtesy of iStock).QIAGEN N.V. (Hilden, Germany), a provider of sample and assay technologies, has acquired OmicSoft Corporation (Cary, NC, USA), which focuses on biomarker data management, visualization, and analysis.

QIAGEN’s broad range of consumables includes complete kits for predefined applications in sample preparation and analysis and also individual enzymes and reagents that research laboratories can use to develop their own applications. QIAGEN also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result. Its solutions find applications in human healthcare, forensics, veterinary testing, food safety, pharma and biotech companies, and life sciences research.

OmicSoft designs and develops bioinformatics, next generation sequencing, and cancer genomics software for biomarker data management, visualization, and analysis. Its suite of software solutions enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets, and share the results with colleagues.

The acquisition will provide QIAGEN access to OmicSoft’s multi-omics data management infrastructure solution as well as curated ‘omics’ data sets that complement its bioinformatics portfolio for gaining insights into complex biological data. With the addition of OmicSoft, QIAGEN will be able to offer solutions across the full spectrum of data management and interpretation needs.

“The addition of OmicSoft to QIAGEN’s portfolio of Sample to Insight solutions reinforces our position as the gold standard for analysis and interpretation of complex biological data across many different disciplines,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
“The OmicSoft team has deep expertise that will enable QIAGEN to better support customers in managing vast data sets and gaining actionable insights for discovery and translational research,” said Dr. Laura Furmanski, Senior Vice President and Head of the Bioinformatics Business Area at QIAGEN. “The market opportunity is significant given the expanding use of multiple ‘omics’ data in research and clinical healthcare. We intend to integrate the OmicSoft solutions into our full bioinformatics interpretation portfolio, and make it a key differentiator in our Sample to Insight offerings.”

Related Links
QIAGEN
OmicSoft



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

20 May 2022
Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business
QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.
Read More
02 Jul 2021
Qiagen Partners with Sysmex for Development and Commercialization of Cancer Companion Diagnostics
QIAGEN N.V. (Venlo, Netherlands) and Sysmex Corporation (Kobe, Japan) have entered into a global strategic alliance for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Read More
14 Aug 2020
QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Read More
13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More

Additional news

16 Aug 2022
BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
Read More
05 Aug 2022
Bio-Rad Acquires Curiosity Diagnostics from Scope Fluidics
Bio-Rad Laboratories (Hercules, CA, USA) has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (Warsaw, Poland) for a total consideration of up to USD 170 million, consisting of approximately USD 100 million in cash, and up to USD 70 million in future milestone payments.
Read More
04 Aug 2022
Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure
The global capsule endoscopy system market is expanding at a rapid pace due to the rising demand for the procedure using minimally invasive diagnostic techniques, increase in the introduction of technologically advanced capsules, growth in the geriatric population, and rising prevalence of cancer around the world.
Read More
02 Aug 2022
PerkinElmer Divests Other Businesses to Focus on Life Sciences and Diagnostics
PerkinElmer, Inc. (Waltham, MA; USA) has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital (New York, NY, USA) for total consideration of USD 2.45 billion in cash.
Read More
31 Jul 2022
Labcorp to Spin Off Clinical Development Business
LabCorp Diagnostics (Burlington, NC, USA) has announced that its board of directors has authorized the company to pursue a spin-off of its wholly owned Clinical Development business to shareholders through a tax-free transaction.
Read More
31 Jul 2022
IFCC Celebrates 70 Years of Advancing Science of Laboratory Medicine and In Vitro Diagnostics
The IFCC is celebrating 70 years (1952 – 2022) of enormous achievements that have been extraordinary and impressive, contributing to its mission of “Advancing excellence in laboratory medicine for better healthcare worldwide”.
Read More
27 Jul 2022
Medlab Asia and Asia Health to Host First-Ever Live, In-Person Event in Thailand
Informa Markets (London, UK), in partnership with Impact Muang Thong Thani (Nonthaburi, Thailand), have confirmed that Medlab Asia and Asia Health will take place in Thailand for the first time when the co-located events return live and in-person at the Impact Exhibition Center, Bangkok, from 19-21 October 2022.
Read More
25 Jul 2022
Registration Opens for RSNA 2022
Registration is now open for the Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) 108th Scientific Assembly and Annual Meeting to be held at McCormick Place Chicago, Nov. 27 – Dec. 1, 2022.
Read More
25 Jul 2022
Bioperfectus and ELITechGroup Collaborate for Monkeypox Virus Testing Across Europe
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) and ELITechGroup S.p.A. (Puteaux, France) have entered into a strategic partnership for monkeypox virus testing across Europe.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions